Clinical Trial Update: Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ritonavir-boosted atazanavir or darunavir with optimized NRTI backbone for second-line HIV-1 treatment has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• ATAZANAVIR (atazanavir)
• Darunavir (darunavir)
• Ritonavir-boosted atazanavir (atazanavir/ritonavir)
• Ritonavir-boosted darunavir (darunavir boosted with ritonavir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: HIV | Phase 3 | Status: WITHDRAWN